Jan Trøst Jørgensen

Loop profile ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 12

Top Topics

Positive Breast Cancer

Tyrosine Kinase

Epidermal Growth Factor Receptor

Top Venues

Annals of translational medicine

Translational lung cancer research

Expert review of molecular diagnostics

This page only lists publications with an associated author ORCID identifier.

Publications

Jan Trøst Jørgensen, Edyta Maria Urbanska, Jens Mollerup
MET targeted therapy in non-small cell lung cancer patients with MET exon 14-skipping mutations. Translational lung cancer research 13 (4) (2024)
Jan Trøst Jørgensen
The impact of companion diagnostic testing on medical decision making and IVD regulations. Expert review of molecular diagnostics 24 (4) (2024)
Jan Trøst Jørgensen
The impact of companion diagnostic testing on medical decision making and IVD regulations. Expert review of molecular diagnostics (2024)
Jan Trøst Jørgensen, Kristian Egebjerg, Anne-Vibeke Lænkholm, Morten Mau Sorensen
Human Epidermal Growth Factor Receptor 2 Pan Tumor Indication for Trastuzumab Deruxtecan. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Jan Trøst Jørgensen, Edyta Maria Urbanska, Jens Mollerup
MET targeted therapy in non-small cell lung cancer patients with MET exon 14-skipping mutations. Translational lung cancer research 13 (4) (2024)
Jens Mollerup, Jan Trøst Jørgensen
The Different Roles of MET in the Development and Treatment of Cancer. Cancers 15 (20) (2023)
Jan Trøst Jørgensen
Twenty-five years with HER2 targeted therapy. Annals of translational medicine 12 (3) (2023)
Jan Trøst Jørgensen
Twenty-five years with HER2 targeted therapy. Annals of translational medicine 12 (3) (2023)
Jan Trøst Jørgensen
Missing Companion Diagnostic for US Food and Drug Administration-Approved Hematological and Oncological Drugs. JCO precision oncology 6 (2022)
Jan Trøst Jørgensen, Jens Mollerup
Companion Diagnostics and Predictive Biomarkers for MET-Targeted Therapy in NSCLC. Cancers 14 (9) (2022)
Jan Trøst Jørgensen
Predictive biomarkers and clinical evidence. Basic & clinical pharmacology & toxicology 128 (5) (2021)
Jan Trøst Jørgensen
Twenty Years with Personalized Medicine: Past, Present, and Future of Individualized Pharmacotherapy. The oncologist 24 (7) (2019)